Improvement in the Definition of Anti-HLA Antibody Profile in Highly Sensitized Patients

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 Feb 4

PMID 28158255

Citations 1

Authors

Juan Irure

Esther Asensio

Emilio Rodrigo

Inigo Romon

Javier Gomez

Manuel Arias

Marcos Lopez-Hoyos

David San Segundo

Affiliations

Soon will be listed here.

Abstract

The definition of anti-HLA antibody profile in highly sensitized patients on a waiting list is crucial when virtual crossmatch is used in organ allocation systems, but also when used to identify the true deleterious anti-HLA antibodies. Here we propose different levels of risk based on the results of anti-HLA antibody testing in neat serum (N) and after sera dilution (DIL) and C1q test in 18 highly sensitized patients. This group was heterogeneous in terms of anti-HLA antibody titers and their ability to fix complement. After dilution, 15 out of 18 patients (83.3%) showed a reduction of positive bead counts whereas 4 patients showed a prozone effect and complement fixation was demonstrated. The high dilution of sera and ascertaining the complement fixation allow the accurate definition of risk anti-HLA antibody profiles in highly sensitized patients, as demonstrated in 5 of the sensitized patients who were transplanted.

Citing Articles

Application, technical issues, and interpretation of C1q for graft outcome.

Tyan D Curr Opin Organ Transplant. 2017; 22(5):505-510.

PMID: 28723698 PMC: 5662152. DOI: 10.1097/MOT.0000000000000454.

References

Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen J, Mooney N . Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013; 369(13):1215-26. DOI: 10.1056/NEJMoa1302506. View

Tambur A, Herrera N, Haarberg K, Cusick M, Gordon R, Leventhal J . Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information. Am J Transplant. 2015; 15(9):2421-30. DOI: 10.1111/ajt.13295. View

Berth M . Complement Interference Is Not the Same as a Prozone Phenomenon. Am J Transplant. 2015; 16(5):1638. DOI: 10.1111/ajt.13650. View

Minucci P, Grimaldi V, Casamassimi A, Cacciatore F, Sommese L, Picascia A . Methodologies for anti-HLA antibody screening in patients awaiting kidney transplant: a comparative study. Exp Clin Transplant. 2011; 9(6):381-6. View

Bray R, Gebel H . Strategies for human leukocyte antigen antibody detection. Curr Opin Organ Transplant. 2009; 14(4):392-7. DOI: 10.1097/mot.0b013e32832d31c7. View

Jackson A . The Virtual Crossmatch: An Essential Tool for Transplanting Sensitized Patients. Clin Transpl. 2015; :131-6. View

Morris G, Phelan D, Jendrisak M, Mohanakumar T . Virtual crossmatch by identification of donor-specific anti-human leukocyte antigen antibodies by solid-phase immunoassay: a 30-month analysis in living donor kidney transplantation. Hum Immunol. 2010; 71(3):268-73. DOI: 10.1016/j.humimm.2010.01.003. View

Endres R, Kleinman S, Carrick D, Steele W, Wright D, Norris P . Identification of specificities of antibodies against human leukocyte antigens in blood donors. Transfusion. 2010; 50(8):1749-60. PMC: 3061817. DOI: 10.1111/j.1537-2995.2010.02589.x. View

Visentin J, Vigata M, Daburon S, Contin-Bordes C, Fremeaux-Bacchi V, Dromer C . Deciphering complement interference in anti-human leukocyte antigen antibody detection with flow beads assays. Transplantation. 2014; 98(6):625-31. DOI: 10.1097/TP.0000000000000315. View

10.

Guidicelli G, Anies G, Bachelet T, Dubois V, Moreau J, Merville P . The complement interference phenomenon as a cause for sharp fluctuations of serum anti-HLA antibody strength in kidney transplant patients. Transpl Immunol. 2013; 29(1-4):17-21. DOI: 10.1016/j.trim.2013.09.005. View

11.

Tambur A, Ramon D, Kaufman D, Friedewald J, Luo X, Ho B . Perception versus reality?: Virtual crossmatch--how to overcome some of the technical and logistic limitations. Am J Transplant. 2009; 9(8):1886-93. PMC: 4094140. DOI: 10.1111/j.1600-6143.2009.02724.x. View

12.

Tait B, Susal C, Gebel H, Nickerson P, Zachary A, Claas F . Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation. 2012; 95(1):19-47. DOI: 10.1097/TP.0b013e31827a19cc. View

13.

Visentin J, Guidicelli G, Taupin J . Assessing HLA Antibody Strength: Have We Thought About Everything?. Am J Transplant. 2015; 15(12):3271. DOI: 10.1111/ajt.13452. View

14.

Tait B, Hudson F, Brewin G, Cantwell L, Holdsworth R . Solid phase HLA antibody detection technology--challenges in interpretation. Tissue Antigens. 2010; 76(2):87-95. DOI: 10.1111/j.1399-0039.2010.01486.x. View